Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory
The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and sulbactam-durlobactam. The...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Antibiotics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-6382/12/12/1700 |
| _version_ | 1797382261322022912 |
|---|---|
| author | Carmella Russo Romney Humphries |
| author_facet | Carmella Russo Romney Humphries |
| author_sort | Carmella Russo |
| collection | DOAJ |
| description | The rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and sulbactam-durlobactam. These agents are equipped with innovative mechanisms that confer broad Gram-negative activity, notably against certain challenging carbapenemases. While their introduction offers a beacon of hope, clinical microbiology laboratories must navigate the complexities of susceptibility testing for these agents due to their diverse activity profiles against specific β-lactamases and the possibility of acquired resistance mechanisms in some bacterial isolates. This review explores the complexities of these novel antimicrobial agents detailing the intricacies of their application, providing guidance on the nuances of susceptibility testing, interpretation, and result reporting in clinical microbiology laboratories. |
| first_indexed | 2024-03-08T21:03:54Z |
| format | Article |
| id | doaj.art-ba54b1eada0a4120b40963ac74049c40 |
| institution | Directory Open Access Journal |
| issn | 2079-6382 |
| language | English |
| last_indexed | 2024-03-08T21:03:54Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibiotics |
| spelling | doaj.art-ba54b1eada0a4120b40963ac74049c402023-12-22T13:47:56ZengMDPI AGAntibiotics2079-63822023-12-011212170010.3390/antibiotics12121700Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical LaboratoryCarmella Russo0Romney Humphries1Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USAPathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USAThe rapid emergence of multi-drug resistant Gram-negative pathogens has driven the introduction of novel β-lactam combination agents (BLCs) to the antibiotic market: ceftolozane-tazobactam, ceftazidime-avibactam, meropenem-vaborbactam, imipenem-relebactam, cefiderocol, and sulbactam-durlobactam. These agents are equipped with innovative mechanisms that confer broad Gram-negative activity, notably against certain challenging carbapenemases. While their introduction offers a beacon of hope, clinical microbiology laboratories must navigate the complexities of susceptibility testing for these agents due to their diverse activity profiles against specific β-lactamases and the possibility of acquired resistance mechanisms in some bacterial isolates. This review explores the complexities of these novel antimicrobial agents detailing the intricacies of their application, providing guidance on the nuances of susceptibility testing, interpretation, and result reporting in clinical microbiology laboratories.https://www.mdpi.com/2079-6382/12/12/1700antimicrobial susceptibility testingbreakpointsbeta-lactamsbeta-lactam combination |
| spellingShingle | Carmella Russo Romney Humphries Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory Antibiotics antimicrobial susceptibility testing breakpoints beta-lactams beta-lactam combination |
| title | Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory |
| title_full | Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory |
| title_fullStr | Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory |
| title_full_unstemmed | Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory |
| title_short | Approaches to Testing Novel β-Lactam and β-Lactam Combination Agents in the Clinical Laboratory |
| title_sort | approaches to testing novel β lactam and β lactam combination agents in the clinical laboratory |
| topic | antimicrobial susceptibility testing breakpoints beta-lactams beta-lactam combination |
| url | https://www.mdpi.com/2079-6382/12/12/1700 |
| work_keys_str_mv | AT carmellarusso approachestotestingnovelblactamandblactamcombinationagentsintheclinicallaboratory AT romneyhumphries approachestotestingnovelblactamandblactamcombinationagentsintheclinicallaboratory |